https://pittplusme.org/study/2293
The NN9500-4656 Study
This study is not currently recruiting. Please check back at a later time.
STUDY BASICS
Do you want to address your liver health? Do you have non-alcoholic steatohepatitis (NASH)? You may be able to participate in a study that is evaluating three investigational drugs for their ability to treat NASH.
IRB: 20212505
- Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis a dose-ranging, placebo controlled trial
AGE:
18 and up
DURATION:
About 19 months
VISITS:
14 visits & 9 phone calls
LOCATION:
Kaufmann Building - Oakland
COMPENSATION:
Up to $1,150
SHARE STUDY
MEET THE RESEARCHER
Mordechai Rabinovitz
Mordechai Rabinovitz, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh. A graduate of Tel-Aviv University in Israel, Dr. Rabinovitz’s research interests include assessment and treatment of chronic viral hepatitis as well as developing new therapies for non-alcoholic fatty liver disease.